Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection
- Autores
- Srinivasan, Venkatramanujam; Cardinali, Daniel Pedro; Srinivasan, Uddanapalli S.; Kaur, Charanjit; Brown, Gregory M.; Spence, David Warren; Hardeland, Rudiger; Pandi Perumal, Seithikurippu R.
- Año de publicación
- 2011
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Sleep disorders constitute major nonmotor features of Parkinson's disease (PD) that have a substantial effect on patients' quality of life and can be related to the progression of the neurodegenerative disease. They can also serve as preclinical markers for PD, as it is the case for rapid eye movement (REM)-associated sleep behavior disorder (RBD). Although the etiology of sleep disorders in PD remains undefined, the assessment of the components of the circadian system, including melatonin secretion, could give therapeutically valuable insight on their pathophysiopathology. Melatonin is a regulator of the sleep/wake cycle and also acts as an effective antioxidant and mitochondrial function protector. A reduction in the expression of melatonin MT1 and MT2 receptors has been documented in the substantia nigra of PD patients. The efficacy of melatonin for preventing neuronal cell death and for ameliorating PD symptoms has been demonstrated in animal models of PD employing neurotoxins. A small number of controlled trials indicate that melatonin is useful in treating disturbed sleep in PD, in particular RBD. Whether melatonin and the recently developed melatonergic agents (ramelteon, tasimelteon, agomelatine) have therapeutic potential in PD is also discussed.
Fil: Srinivasan, Venkatramanujam. No especifíca;
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Srinivasan, Uddanapalli S.. No especifíca;
Fil: Kaur, Charanjit. No especifíca;
Fil: Brown, Gregory M.. University of Toronto; Canadá
Fil: Spence, David Warren. No especifíca;
Fil: Hardeland, Rudiger. Universität Göttingen; Alemania
Fil: Pandi Perumal, Seithikurippu R.. No especifíca; - Materia
-
AGOMELATINE
INSOMNIA
LIGHT THERAPY
MELATONIN
OXIDATIVE STRESS
PARKINSON'S DISEASE
RAMELTEON
REM SLEEP BEHAVIOR DISORDER
TASIMELTEON - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/192174
Ver los metadatos del registro completo
id |
CONICETDig_e729548378918656698884d90ff114e3 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/192174 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotectionSrinivasan, VenkatramanujamCardinali, Daniel PedroSrinivasan, Uddanapalli S.Kaur, CharanjitBrown, Gregory M.Spence, David WarrenHardeland, RudigerPandi Perumal, Seithikurippu R.AGOMELATINEINSOMNIALIGHT THERAPYMELATONINOXIDATIVE STRESSPARKINSON'S DISEASERAMELTEONREM SLEEP BEHAVIOR DISORDERTASIMELTEONhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Sleep disorders constitute major nonmotor features of Parkinson's disease (PD) that have a substantial effect on patients' quality of life and can be related to the progression of the neurodegenerative disease. They can also serve as preclinical markers for PD, as it is the case for rapid eye movement (REM)-associated sleep behavior disorder (RBD). Although the etiology of sleep disorders in PD remains undefined, the assessment of the components of the circadian system, including melatonin secretion, could give therapeutically valuable insight on their pathophysiopathology. Melatonin is a regulator of the sleep/wake cycle and also acts as an effective antioxidant and mitochondrial function protector. A reduction in the expression of melatonin MT1 and MT2 receptors has been documented in the substantia nigra of PD patients. The efficacy of melatonin for preventing neuronal cell death and for ameliorating PD symptoms has been demonstrated in animal models of PD employing neurotoxins. A small number of controlled trials indicate that melatonin is useful in treating disturbed sleep in PD, in particular RBD. Whether melatonin and the recently developed melatonergic agents (ramelteon, tasimelteon, agomelatine) have therapeutic potential in PD is also discussed.Fil: Srinivasan, Venkatramanujam. No especifíca;Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Srinivasan, Uddanapalli S.. No especifíca;Fil: Kaur, Charanjit. No especifíca;Fil: Brown, Gregory M.. University of Toronto; CanadáFil: Spence, David Warren. No especifíca;Fil: Hardeland, Rudiger. Universität Göttingen; AlemaniaFil: Pandi Perumal, Seithikurippu R.. No especifíca;SAGE Publications2011-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/192174Srinivasan, Venkatramanujam; Cardinali, Daniel Pedro; Srinivasan, Uddanapalli S.; Kaur, Charanjit; Brown, Gregory M.; et al.; Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection; SAGE Publications; Therapeutic Advances in Neurological Disorders; 4; 5; 3-2011; 297-3171756-2864CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1177/1756285611406166info:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.1177/1756285611406166info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:56:42Zoai:ri.conicet.gov.ar:11336/192174instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:56:42.345CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection |
title |
Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection |
spellingShingle |
Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection Srinivasan, Venkatramanujam AGOMELATINE INSOMNIA LIGHT THERAPY MELATONIN OXIDATIVE STRESS PARKINSON'S DISEASE RAMELTEON REM SLEEP BEHAVIOR DISORDER TASIMELTEON |
title_short |
Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection |
title_full |
Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection |
title_fullStr |
Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection |
title_full_unstemmed |
Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection |
title_sort |
Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection |
dc.creator.none.fl_str_mv |
Srinivasan, Venkatramanujam Cardinali, Daniel Pedro Srinivasan, Uddanapalli S. Kaur, Charanjit Brown, Gregory M. Spence, David Warren Hardeland, Rudiger Pandi Perumal, Seithikurippu R. |
author |
Srinivasan, Venkatramanujam |
author_facet |
Srinivasan, Venkatramanujam Cardinali, Daniel Pedro Srinivasan, Uddanapalli S. Kaur, Charanjit Brown, Gregory M. Spence, David Warren Hardeland, Rudiger Pandi Perumal, Seithikurippu R. |
author_role |
author |
author2 |
Cardinali, Daniel Pedro Srinivasan, Uddanapalli S. Kaur, Charanjit Brown, Gregory M. Spence, David Warren Hardeland, Rudiger Pandi Perumal, Seithikurippu R. |
author2_role |
author author author author author author author |
dc.subject.none.fl_str_mv |
AGOMELATINE INSOMNIA LIGHT THERAPY MELATONIN OXIDATIVE STRESS PARKINSON'S DISEASE RAMELTEON REM SLEEP BEHAVIOR DISORDER TASIMELTEON |
topic |
AGOMELATINE INSOMNIA LIGHT THERAPY MELATONIN OXIDATIVE STRESS PARKINSON'S DISEASE RAMELTEON REM SLEEP BEHAVIOR DISORDER TASIMELTEON |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Sleep disorders constitute major nonmotor features of Parkinson's disease (PD) that have a substantial effect on patients' quality of life and can be related to the progression of the neurodegenerative disease. They can also serve as preclinical markers for PD, as it is the case for rapid eye movement (REM)-associated sleep behavior disorder (RBD). Although the etiology of sleep disorders in PD remains undefined, the assessment of the components of the circadian system, including melatonin secretion, could give therapeutically valuable insight on their pathophysiopathology. Melatonin is a regulator of the sleep/wake cycle and also acts as an effective antioxidant and mitochondrial function protector. A reduction in the expression of melatonin MT1 and MT2 receptors has been documented in the substantia nigra of PD patients. The efficacy of melatonin for preventing neuronal cell death and for ameliorating PD symptoms has been demonstrated in animal models of PD employing neurotoxins. A small number of controlled trials indicate that melatonin is useful in treating disturbed sleep in PD, in particular RBD. Whether melatonin and the recently developed melatonergic agents (ramelteon, tasimelteon, agomelatine) have therapeutic potential in PD is also discussed. Fil: Srinivasan, Venkatramanujam. No especifíca; Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Srinivasan, Uddanapalli S.. No especifíca; Fil: Kaur, Charanjit. No especifíca; Fil: Brown, Gregory M.. University of Toronto; Canadá Fil: Spence, David Warren. No especifíca; Fil: Hardeland, Rudiger. Universität Göttingen; Alemania Fil: Pandi Perumal, Seithikurippu R.. No especifíca; |
description |
Sleep disorders constitute major nonmotor features of Parkinson's disease (PD) that have a substantial effect on patients' quality of life and can be related to the progression of the neurodegenerative disease. They can also serve as preclinical markers for PD, as it is the case for rapid eye movement (REM)-associated sleep behavior disorder (RBD). Although the etiology of sleep disorders in PD remains undefined, the assessment of the components of the circadian system, including melatonin secretion, could give therapeutically valuable insight on their pathophysiopathology. Melatonin is a regulator of the sleep/wake cycle and also acts as an effective antioxidant and mitochondrial function protector. A reduction in the expression of melatonin MT1 and MT2 receptors has been documented in the substantia nigra of PD patients. The efficacy of melatonin for preventing neuronal cell death and for ameliorating PD symptoms has been demonstrated in animal models of PD employing neurotoxins. A small number of controlled trials indicate that melatonin is useful in treating disturbed sleep in PD, in particular RBD. Whether melatonin and the recently developed melatonergic agents (ramelteon, tasimelteon, agomelatine) have therapeutic potential in PD is also discussed. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-03 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/192174 Srinivasan, Venkatramanujam; Cardinali, Daniel Pedro; Srinivasan, Uddanapalli S.; Kaur, Charanjit; Brown, Gregory M.; et al.; Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection; SAGE Publications; Therapeutic Advances in Neurological Disorders; 4; 5; 3-2011; 297-317 1756-2864 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/192174 |
identifier_str_mv |
Srinivasan, Venkatramanujam; Cardinali, Daniel Pedro; Srinivasan, Uddanapalli S.; Kaur, Charanjit; Brown, Gregory M.; et al.; Therapeutic potential of melatonin and its analogs in Parkinson's disease: Focus on sleep and neuroprotection; SAGE Publications; Therapeutic Advances in Neurological Disorders; 4; 5; 3-2011; 297-317 1756-2864 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1177/1756285611406166 info:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.1177/1756285611406166 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
SAGE Publications |
publisher.none.fl_str_mv |
SAGE Publications |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269418724261888 |
score |
13.13397 |